In summary, the expression of immune-checkpoint proteins PD-L1 and PD-L2 is primarily tumor-driven and associated with invasive endometrioid and serous adenocarcinoma, and more commonly with myometrial invasion. This evidence concerns the gene CD274 and neoplasm.